We have tested the effect of a range of antisense oligodeoxyribonucleotides (ODN) directed against the human estrogen receptor alpha (ERa) on ERa protein expression and function. Antisense ERa ODN transfected into the ERa-positive human breast carcinoma cell line MCF7-K2 showed variable responses dependent on the oligo used. The most active antisense ODN (oligo 7) decreased the levels of ERa protein by 61% as measured by Western blot analysis. Exogenous 17b-estradiol (17b-E 2 ), but not 17a-E 2 , augmented this effect, with a threshold effect at 10 28 M 17b-E 2 . The inhibitory effect of antisense ERa oligo 7 was confirmed by measurement of functional ERa protein.
INTRODUCTION N
ATURAL AND SYNTHETIC ESTROGENS exert their physiologic and pharmacologic effects on target tissues by interacting with the cognate estrogen receptor (ERa), a member of the steroid/thyroid hormone superfamily of nuclear transcription factors (Evans, 1988; O'Malley, 1990; Ribeiro et al., 1995) . ERa antagonists that inhibit estrogen-dependent breast and endometrial pathologies while also providing ERa agonist activity on the skeleton and cardiovascular system (SERM) have been developed for the treatment of estrogen-deficient states in women (Mijatovic et al., 1999; Mitlak and Cohen, 1999; Poletti, 1999) . Unfortunately, the reinitiation of uterine bleeding and increased breast tenderness are two of many symptoms of SERM therapy in women that cause discontinuation of long-term treatment (Schiff et al., 1998) .
To inhibit the dysfunctional uterine bleeding and, to a lesser extent, breast tenderness, a progestin is often added to the hormone replacement therapy (HRT). However, progestins often cause premenstrual-type symptoms that also cause patients to discontinue treatment (Al-Azzawi and Habiba, 1994) . If the adverse effects on the endometrium of unopposed estrogens could be blocked, the addition of a progestin to a patient's HRT would not be needed, and problems associated with progestin use would be avoided. Simultaneously, the systemic effects of the estrogen would be maintained without the reinitiation of uterine bleeding. These data suggest that an alternative treatment method for estrogen-sensitive tissues might be useful.
As the expression and intracellular concentration of ERa are central to the progression of estrogen-dependent malignancies and there is clear evidence that ERa levels must achieve a critical level for ERa-mediated events to occur (Vanderbilt et al., 1987; Weeb et al., 1992) , a reduction in ERa protein levels in a target tissue, such as the breast or uterus, to below a critical level might prevent the activation of ERa-dependent transcription pathways (Curtis and Korach, 1990) .
Antisense oligodeoxyribonucleotide (ODN) sequences used in gene therapy that show tissue specificity have been used to ameliorate the symptoms of some clinical conditions and to significantly improve quality of life (Yacyshyn et al., 1998; Sereni et al., 1999; Warzocha, 1999) . Additionally, data suggest that many ERa-dependent tissues are amenable to transfection, with some studies showing specific inhibition of gene activity in laboratory animals (L'Horset et al., 1994; Arslan et al., 1995; Moreau et al., 1995; Charnock-Jones et al., 1997; Horn et al., 1998) . Therefore, an attractive route to ameliorate the noncontinuance issue for SERM treatment regimens would be the use of topical antisense ODN gene therapy against the human ERa in the human uterus.
This study was designed to test the hypothesis that antisense ODN directed against the human ERa might reduce cellular ERa concentrations in a human cell line. To study the action of the antisense ODN, we have used a subclone of the well-characterized human breast cancer cell line MCF7. The data presented show that three antisense ERa ODN sequences inhibit ERa protein concentrations. The antisense effect is enhanced by exogenous 17b-estradiol (17b-E 2 ) through a mechanism that increases ODN uptake, which augments ERa clearance, but not through the normal MCF7 cell proteosome-dependent pathway (Alarid et al., 1999; Nawaz et al., 1999) . One of the antisense ODN specifically inhibits 17b-E 2 -dependent MCF7 cell proliferation.
MATERIALS AND METHODS

ODN design and synthesis
Antisense ODN were designed to encompass the translation start site (23 to 15 bp) and both coding and noncoding regions of the human ERa gene (Greene et al., 1986; Santagati et al., 1997) . Control sequences were the respective sense strands, and for oligo 7, an additional control was the nucleotides contained in the antisense sequence arranged at random to generate a scrambled sequence. The antisense ODN, numbered oligo 1 to oligo 6, ( Fig. 1 ) have been described elsewhere (oligo 1; GACATGCGCTGCGTCGCC; oligo 2, GCCAGTACCAAT-GACAAG; oligo 3, TGTGCCTGGCTAGAGATC; oligo 4, GGGTCAGTGGGTTCTTTT; oligo 5 GTGTCTCCGAGCC-CGCTG; oligo 6 TGGACAGTAGCGAGTCAG [Santagati et al., 1997] ). To ensure the uniqueness of the sequences, they were aligned against all known human sequences on the sequence databases. All sequences were unique to human ERa except the antisense sequence designed to encompass the translation start site (oligo 7, GACCATGACCATGACCCT) that aligned with the rat and mouse ERa and the human, mouse, and rat estrogen receptor-related alpha1 (ERR-1a) genes alone (White et al., 1987; Giguere et al., 1988; Shigeta et al., 1997) . The ODN and RT-PCR primer sequences (Table 1) were commercially synthesized (Bioline Ltd., London, U.K.) and purified by both PAGE electrophoresis and HPLC prior to use.
Cell culture, transfection, and protein extraction
MCF7-K2 cells (Katzenellenbogen et al., 1987) obtained from the Breast Cancer Unit, Glenfield Hospital (Leicester, U.K.) were maintained in phenol red-free Dulbecco's modified Eagle's medium (DMEM) (GIBCO-BRL, Paisley, Scotland) containing 10% fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/ml streptomycin, and 2 mM L-glutamine (GIBCO-BRL) in a humidified 5% CO 2 in air atmosphere. For transfection, MCF7-K2 cells were subcultured to 10-cm diameter plastic Petri dishes with the aid of trypsin-EDTA at a density of 4 3 10 6 cells/cm 2 in the above medium and allowed to adhere for 24 hours. Cells were then washed twice with sterile phosphatebuffered saline (PBS), covered with serum-free medium, and transfected with DNA-lipofectamine complexes at a 1:8 ratio according to the manufacturer's instructions (GIBCO-BRL).
Crystalline 17b-E 2 and 17a-E 2 were purchased from SigmaAldrich (Poole, Dorset, U.K.), and the proteosome inhibitor MG-132 was from CN Biosciences (Nottingham, U.K.). E 2 and MG-132 solutions in ethanol and dimethylsulfoxide (DMSO), respectively, were diluted in serum-free medium and added to cultures at the indicated concentrations. To control for possible solvent effects, control cultures contained 0.1% ethanol or 0.2% DMSO in serum-free medium. After a further 24-hour incubation, cells were washed with sterile PBS and scraped from the plastic substratum in GETD buffer (10% glycerol, 1.5 mM EDTA, 10 mM Tris-HCl, pH 7.6, 10 mM dithiothreitol [DTT] ) in the absence of protease inhibitors and subjected to five rounds of freeze-fracture. Protein concentrations were measured using the Bradford microassay (Bradford, 1976 ) (BioRad Laboratories, Hemel Hempstead, Hertfordshire, U.K.), with bovine serum albumin (BSA) as standard and samples TAYLOR ET AL. 220 FIG. 1. Schematic representation of antisense ODN designed against human ERa. ERa target sequences oligo 1-oligo 6 are depicted by the numbered boxes corresponding to translated and nontranslated regions of the human ERa mRNA sequence. The sequences of oligo 1-oligo 7 correspond to nucleotides 2117-299, 495/512, 1140-1157, 4134-4151, 302-320, 539-557, and 23-15 of the human ERa cDNA, respectively (Santagati et al., 1997 
Western blot analysis
Total cellular protein (12 mg) was separated on 12% precast denaturing SDS-PAGE gels (Novex, San Diego, CA) at 125 V constant voltage for 1.5 hours. After transfer to nitrocellulose membranes (Hybond-C) (Amersham PLC, Amersham, Buckinghamshire, U.K.) in transfer buffer (12 mM Tris, 96 mM glycine, 20% methanol), membranes were blocked with 3% nonfat milk powder in PBS for 20 minutes. Membranes were then incubated at 4°C for 18 hours with monoclonal primary ERa antibody (clone 05-394, Upstate Biotechnology, Lake Placid, NY) diluted to 2 mg/ml in the blocking solution. After five washes with deionized water, membranes were incubated with secondary antimouse horseradish peroxidase (HRP)-linked antibody (1:3000) (Amersham) in 3% blocking solution at ambient temperature for 1.5 hours. After a further five washes with water, a 5-minute wash with 0.05% Tween-PBS, and a further five washes with water, the protein-antibody complexes were visualized with enhanced chemiluminescence (ECL) detection, according to the manufacturer's protocol (Amersham), and exposure to x-ray film (Kodak Biomax ML) (Integra Biosciences Ltd, Letchworth, Hertfordshire, U.K.) for up to 5 minutes. In some experiments, human recombinant ERa (Affinity Bioreagents Inc., Golden, CO) was used to create a curve of standards within the assay. The densities of the visualized bands were obtained by video-assisted densitometry (NIH Image program Version Beta 3b, 1998, modified for Windows 95/98 by Scion Corporation; http://www.scioncorp.com) and corrected for by the amount of b-actin (1:5000, clone AC-74, Sigma) from replica blots.
Radioligand binding
3 H-E 2 binding to MCF7-K2 extracts was performed essentially as described (Campisi et al., 1993) . Briefly, initial studies to find maximum binding capacity used 200-300-mg aliquots of MCF7-K2 extract in triplicate adjusted to give a volume of 250 ml in GETD buffer and incubated with a range of 3 H-E 2 (79.5 Ci/mmol) concentrations (Amersham) in GETD buffer at 4°C for 18 hours. Nonspecific binding was determined in the presence of 100-fold excess of unlabeled 17b-E 2 in duplicate. Bound radioactivity was separated from free radioactivity by incubation with 500 ml dextran-coated charcoal in PBS for 20 minutes at 4°C, followed by centrifugation at 1800g for 20 minutes. An aliquot (500 ml) of the supernatant was counted by bscintillation counting for 5 minutes. Maximum binding was found to be 6 3 10 4 cpm of 3 H-E 2 , and this amount of 3 H-E 2 , 200 mg cell extract, and a 100-fold excess of unlabeled 17b-E 2 were used in subsequent binding assays, with separation and counting as described.
Fluorescence photomicroscopy
Cells were plated at a density of 5 3 10 4 to polytetrafluoroethane-coated multispot slides (Hendley, Loughton, Essex, U.K.) contained in a sterile 10-cm Petri dish. After 24-hours attachment, the cells were transfected with fluorescein isothiocyanate (FITC)-labeled antisense oligo 7 in lipofectamine, as described, and immediately treated with up to 10 26 M 17b-E 2 in serum-free medium. After 24 hours, cells were washed twice with PBS and then fixed with 4% paraformaldehyde in serum-free medium for 5 minutes. After two further washes with PBS, the slides were mounted in aquamount (BDH, Poole, Dorset, U.K.) and stored at 4°C in the dark until photographed on a Zeiss Axioplan II microscope fitted with a fluorescent attachment at 530-585-nm excitation onto Fujichrome ASA800 film.
RNA preparation and RT-PCR analysis
MCF7-K2 cells were transfected or nontransfected (controls) and treated with 17b-E 2 as described. After 24 hours, cells were washed twice with PBS and lysed in TRIZOL reagent (GIBCO-BRL). Total RNA was prepared according to the manufacturer's instructions and stored at 280°C. Total RNA (1 mg) was electrophoresed on 1.2% agarose gels to ensure that the RNA was intact.
The primer sequences for ERa and b-actin and assay conditions showing amplification within the exponential part of the amplification have been described elsewhere (Heikinheimo et al., 1995) (Table 1 ). For RT-PCR analysis, 2 ml total cellular RNA was reverse transcribed and subjected to PCR using ExpeRT 100 PCR kits (ThermoHybaid, Teddington, Middlesex, U.K.) according to the manufacturer's one-tube protocol. The level of amplicon was corrected by that produced with specific b-actin primers. The RT conditions were 48°C for 30 minutes, 95°C for 2 minutes. PCR was performed with 10 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 68°C for 1 minute, followed by 25 further cycles with the exception that primer extension at 68°C for 1 minute was extended for 5 seconds on each further cycle. Finally, the reaction was incubated at 68°C for 10 minutes to fully extend all amplified products. Amplification of the housekeeping gene b-actin was similar, except the annealing temperature was 54°C. Thirty or forty percent of the reaction mixture was separated on 1.8% agarose gels impreg- (Heikinheimo et al., 1995) . nated with 0.5 mg/ml ethidium bromide, and the amount of signal was measured by video-assisted densitometry.
Growth curves
Stock cultures of MCF7-K2 cells were subcultured for three passages and maintained in E 2 -deficient medium. This medium consists of phenol red-free DMEM containing 5% charcoalstripped FBS (batch AHM9371, Hyclone, Logan, UT), 50 U/ml penicillin, 50 mg/ml streptomycin, and 2 mM L-glutamine. For the actual growth experiments, cells were plated on 96-well plates at a seeding density of 5000 cells per well. After 24 hours, the cells were transfected in the absence of serum (as described) for 24 hours. The medium was then exchanged for phenol red-free DMEM medium containing 1% charcoal-stripped FBS, 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine, and 0.12 U/ml bovine insulin supplemented with up to 10 26 M of either 17a-E 2 or 17b-E 2 (Malet et al., 1988) . The medium was changed daily for up to 7 days. At the end of the culture period, cell density was assessed with the XTT formazan dye production assay (Roche Diagnostics, Ltd., Lewes, East Sussex, U.K.) for 2 hours, according to the manufacturer's instructions. XTT absorption was measured at 490 nm with a Bio-Rad model 450 ELISA plate reader with a reference absorbance set at 595 nm.
RESULTS
Characterization of MCF7-K2 cells
To ensure that the phenotype of the MCF7-K2 cells used in this study corresponded with that detailed in the literature, 3 H-E 2 binding, proteosomal degradation, and the growth characteristics of these cells were assessed. Binding of 3 H-E 2 to MCF7-K2 cell extracts showed the presence of a functional ERa ( 18.3 6 2.3 108 9.9 6 2.5* 70 5.6 6 1.5** 80**** 10 28 17.3 6 2.6 102 9.0 6 2.5* 64 1.0 6 0.6** 13**** 10 27 12.1 6 2.4 71 10.0 6 2.6 71 1.0 6 0.6** 14**** 10 26 12.5 6 1.6 74 8.7 6 2.6 62 1.2 6 1.0** 18**** a Data are presented as the amount of 3 H-E 2 binding in fmol/mg of cellular protein and are the mean 6 SEM of three independent experiments performed in triplicate.
*p , 0.05, **p , 0.01, transfected compared with nontransfected cultures, ANOVA with Tukey's significant difference test. To indicate the proportional effect of added E 2 , data are also normalized to untreated cultures and presented as % of untreated control. ***p , 0.01, ****p , 0.001, E 2 -treated compared with untreated, two-way ANOVA with Tukey's significant difference test.
2). Specific 3 H-E 2 binding increased with dose and reached a plateau at , 10 4 cpm, with no appreciable increase in nonspecific binding up to 6 3 10 4 cpm (Fig. 2) . The calculated K d and B max were 3.9 6 1.5 nM and 32 6 3.4 fmol/mg protein (n 5 6), respectively. As 3 H-E 2 at 6 3 10 4 cpm did not show appreciable increased nonspecific binding, the amount of total 3 H-E 2 used in subsequent binding assays to show that the antisense ERa ODN might also affect functional ERa protein (Table 2 ) was set to 6 3 10 4 cpm.
Because exogenous 17b-E 2 enhances ERa protein degradation in MCF7-K1 but not in MCF7-K2 cells through the proteosome (Aronica and Katzenellenbogen, 1993; El Khissiin and Leclercq, 1999; Ing and Ott, 1999) , we postulated that 17b-E 2 -induced ERa protein degradation in MCF7-K2 cells would not occur. To test this possibility, MCF7-K2 cells were treated with 10 28 M 17b-E 2 (the dose that significantly enhances antisense ERa oligo 7 action and ERa degradation through the proteosome in MCF7-K1 cells) for up to 24 hours in the presence and absence of the proteosome inhibitor MG-132 (Fig. 3) . 17b-E 2 had no effect on the degradation of ERa over the duration of the experiment (Fig. 3) . The addition of the proteosome inhibitor MG-132 to 17b-E 2 -treated cultures had no effect on ERa protein levels (Fig. 3) . This model suggests that any reduction in ERa protein levels observed would, therefore, be due to a direct effect of antisense ODN action and not 17b-E 2 -induced proteosomal degradation of receptor.
MCF7-K2 cells treated with vehicle (0.1% ethanol) in 1% charcoal-stripped serum proliferated weakly compared with untreated cultures (Fig. 4) but with a population doubling time of 7-8 days. The observed doubling time is similar to that found in the literature (Boccuzzi et al., 1994) . Similarly, cells treated with 10 28 M 17b-E 2 did not proliferate above that of untreated cell cultures or vehicle-treated cultures, whereas MCF7-K2 cells showed an increased proliferation rate (, 2.5-3 days) in response to exogenous 17b-E 2 (Fig. 4) .
ANTISENSE ERa DECREASES ER FUNCTION 223 FIG. 3. MCF7-K2
ERa protein is not degraded via the proteosome. Protein extracts (12 mg) from MCF7 cells treated with 17b-E 2 (10 28 M) in the absence (solid circles) or presence of MG-132 (open circles) for the times indicated were subjected to Western blot analysis as described in Materials and Methods. Data are the mean 6 SD of six experiments performed in triplicate (n 5 6) (data were not significantly different, ANOVA with Tukey's significant differences test).
FIG. 4.
Characterization of 17b-E 2 -dependent MCF7-K2 cell proliferation. MCF7-K2 cells (5000) plated in estrogen-deficient medium (10% charcoal-stripped serum) for 3 days were treated with vehicle (0.1% ethanol) (open triangles), 10 28 M 17a-E 2 (open circles), or 10 28 M 17b-E 2 (solid circles) for a further 4 days. Medium was changed on days 1 and 3. Growth was assessed using XTT formazan dye conversion at 490 nm. Data are the mean 6 SD of three experiments performed in quadruplicate (n 5 3) (p p , 0.05, p p p , 0.01, p p p p , 0.001, ANOVA with Tukey's significant differences test compared to day 0).
These data suggest that MCF7-K2 cells are an appropriate model to study the effect of antisense ODN on the levels of ERa mRNA, protein, 3 H-E 2 binding, and proliferation in response to 17b-E 2 (Katzenellenbogen et al., 1987; Read et al., 1989) .
Antisense ERa ODN decrease ERa protein expression
To test the hypothesis that antisense ERa ODN inhibits ERa protein synthesis, the levels of ERa protein in MCF7-K2 cell extracts transfected with antisense ERa ODN were analyzed by Western blot analysis. MCF7-K2 cells produce a single immunoreactive signal with a relative molecular mass of , 66-67 kDa (Fig. 5A) . After densitometric analysis and normalization against untreated controls (Fig. 5B) , the data showed that lipofectamine-treated cells and cells transfected with either sense or scrambled ERa ODN sequences had no significant effect on the expression of ERa in MCF7-K2 cells. Oligos 1-6 had no effect on the levels of ERa protein (Fig. 5B) , but oligo 7 reduced the levels of ERa in MCF7-K2 cells by 61% 6 14% (n 5 6) (ANOVA).
To ensure that the decrease in cytoplasmic ERa levels was not an artifact caused by aberrant 17b-E 2 in the culture system altering ERa degradation, transfected MCF7-K2 cells were treated with 10 28 M 17b-E 2 in an attempt to induce similar reductions in ERa concentrations regardless of the oligo transfected. The four sense and antisense oligonucleotides (oligos 2, 3, 5, and 6, Fig. 1 ) previously used to demonstrate autologous downregulation of ERa on ERa expression in MCF7 cells (Santagati et al., 1997) showed no effect on ERa protein levels in the presence of 17b-E 2 (Fig. 5C) . However, cells transfected with oligo 1, oligo 4, or oligo 7 subsequently treated with exogenous 17b-E 2 (Fig. 5C) showed significant ERa protein level reductions of 36% 6 7% for oligo 1 (n 5 6) (Student's t-test) and 62% 6 10% (n 5 6) (Student's t-test) for oligo 4 and 78% 6 4% for oligo 7, respectively.
Because the antisense ODN directed toward the translational start site of human ERa (oligo 7) showed an inhibitory action on ERa expression both in the absence and the presence of 17b-E 2 , only this antisense molecule was tested further.
Specific 17b-E 2 -induced inhibition of ERa protein levels
MCF7-K2 cells transfected with antisense ERa oligo 7 and treated with graded doses of 17b-E 2 showed a marked reduction in ERa protein levels, with a threshold and maximal 36% 6 9.3% (n 5 6) inhibitory effect occurring at 10 28 M 17b-E 2 (Fig.  6) . In contrast, control MCF7-K2 cells (data not shown) and MCF7-K2 cells transfected with the control scrambled ERa ODN did not show significantly reduced protein concentrations when treated with 10 28 M 17b-E 2 (4% 6 11.0%) (Fig. 6) .
Because both E 2 isomers can interact either in a nonspecific manner with the plasma membrane (Nemere and Farach-Carson, 1998) or specifically via a putative membrane ER (Razandi et al., 1999 ) of 17b-E 2 -responsive cells, the enhancing effect of exogenous 17b-E 2 on antisense oligo 7 reduction of ERa protein levels could be attributable to these phenomena. To test this hypothesis, MCF7-K2 cells transfected with a control scrambled (Fig. 7A) or antisense ERa oligo 7 sequence (Fig. 7B) were treated with 17b-E 2 or its inactive isomer 17a-E 2 . As expected, 17b-E 2 significantly enhanced the degradation of ERa by 30%-50% (compare Fig. 7B with Figure 6 ). Equivalent doses of 17a-E 2 had no effect on the relative levels of ERa (Fig. 7B) . Neither E 2 isoform affected the ERa protein concentrations of MCF7-K2 cells transfected with the scrambled ERa oligo 7.
These data suggest that 17b-E 2 enhances the inhibitory effect of the antisense ERa oligo 7 on ERa levels in MCF7-K2 cells by a mechanism that assists in blocking the production of nascent protein rather than increased degradation of existing ERa protein.
Antisense ERa ODN inhibits 3 H-E 2 binding to MCF7 cytoplasmic extracts
MCF7-K2 cells transfected with the antisense ERa ODN showed a significant 58.2% decrease in 3 H-E 2 binding to cell extracts (Table 2) . Cells transfected with the control scrambled ERa oligo 7 sequence and in the absence of exogenous 17b-E 2 showed a nonsignificant 16.5% inhibition of 3 H-E 2 binding compared with control (Table 2 ). These data indicate that the antisense oligo 7 decreases either the ability of MCF7-K2 cell extracts to bind 3 H-E 2 or the levels of cytoplasmic ER protein.
In a parallel study, MCF7-K2 cells were transfected with scrambled or antisense ERa oligo 7 sequences and incubated with 10 29 -10 26 M 17b-E 2 (Table 2 ). Binding to nontransfected control cell extracts was significantly inhibited by high doses of 17b-E 2 (25.7% at 10 26 M), suggesting competition of unlabeled 17b-E 2 with 3 H-E 2 for MCF7-K2 ERa (Table 2) . 3 H-E 2 binding to extracts from cells transfected with the scrambled and antisense ERa oligo 7 was also reduced by 29.9% 6 6.2% and 82.0% 6 5.0% (n 5 9) (ANOVA), respectively, in the presence of 10 26 M exogenous 17b-E 2 compared with the respective controls. The amount of 3 H-E 2 bound to extracts from scrambled oligo 7-transfected cultures treated with 10 26 M 17b-E 2 was not significantly different from the amount bound to similarly treated control cultures (9.9 6 2.6 compared with 12.5 6 1.6 fmol/mg protein) (n 5 9) (ANOVA). However, the amount of 3 H-E 2 bound after 17b-E 2 inhibition with 10 26 M 17b-E 2 in an antisense ODN-transfected culture was significantly lower (1.2 6 1.0 vs. 9.9 6 2.6 or 12.5 6 1.6 fmol/mg protein) (n 5 9) (ANOVA). These data suggest that 17b-E 2 enhances the inhibitory effect of antisense ERa ODN on 3 H-E 2 binding to ERa protein. 
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17b-E 2 enhances antisense ERa ODN effect by increasing ODN uptake
To better understand how 17b-E 2 increases the efficacy of antisense ER oligo 7, MCF7-K2 cells were transfected with FITC-labeled antisense ERa oligo 7 and treated with graded doses of 17b-E 2 (Fig. 8) . The amount of fluorescence is low in untreated cells (Fig. 8A ) but increases with 17b-E 2 treatment and reaches a maximum at about 10 28 M 17b-E 2 (Fig. 8C) . We also noted that at low doses of 17b-E 2 and shorter times, fluorescence is confined to the plasma membrane and cytoplasm (data not shown). At higher doses and longer times, fluorescence signal accumulates in the nucleus. These data indicate that 17b-E 2 enhances antisense ERa oligo 7 transfection efficiency to MCF7-K2 cells.
Antisense ERa ODN has no effect on ERa transcription
To discount the hypothesis that 17b-E 2 affects ERa transcription in antisense ERa oligo-transfected MCF7-K2 cells, we measured the levels of ERa mRNA using RT-PCR (Fig. 9) . The RT-PCR method, including the number of cycles, was validated to ensure the number of cycles was in the linear range for both ERa and b-actin (data not shown) (Heikinheimo et al., 1995) . Antisense ERa oligo 7 had no effect on ERa mRNA levels when compared with ERa mRNA levels in scrambled oligo 7 and control cultures (Fig. 9A) . Additionally, 17b-E 2 had no significant effect on the levels of ERa in any of the control or treated MCF7-K2 cultures (Fig. 8A) . Densitometry measurements of amplicon levels showed an apparent decrease in ERa mRNA levels when compared with control and scrambled ODN-transfected cultures, but the decrease was not found to differ statistically (Fig. 9B) .
MCF7-K2 cell proliferation is enhanced by 17b-E 2 and inhibited by antisense ERa ODN
Initial studies of MCF7-K2 cell proliferation treated with 17b-E 2 at any serum concentration, cell density, and duration of culture showed these cells to be unresponsive to 17b-E 2 (data not shown). However, after three passages of stock cultures in low-E 2 -containing growth medium, MCF7-K2 cells showed both time-dependent (Fig. 4) and dose-dependent responses to 17b-E 2 but not to 17aE 2 (data not shown). Parallel cultures transfected with scrambled oligo 7 or antisense ERa oligo 7 showed no alteration in the basic nonproliferation pattern when treated with 17a-E 2 (Fig. 10A) . In contrast, MCF7-K2 cells transfected with scrambled oligo 7 and treated with graded doses of 17b-E 2 continued to proliferate (Fig. 10B) . MCF7-K2 cells transfected with antisense oligo 7 showed a departure from the normal 17b-E 2 growth patterns, with a dose-dependent loss of cells from the culture (Fig. 10B) . The effect of antisense oligo 7 action on MCF7-K2 cell proliferation was maintained for at least 4 days in culture. Cells transfected with either scrambled or antisense oligo 7 ODN initially showed growthinhibitory effects within the first 24 hours (Fig. 10C) . When medium containing 10 28 M 17b-E 2 was reintroduced to the cultures on day 2, MCF7-K2 cells transfected with scrambled oligo 7 or sense oligo 7 (data not shown) reinitiated cell proliferation and continued to proliferate at the same rate as nontransfected control cultures (Fig. 10C) . However, MCF7-K2 cells transfected with antisense oligo 7 no longer had the capacity to proliferate in response to 10 28 M 17b-E 2 (Fig. 10C) . These data suggest that antisense oligo 7 inhibits the production of ERa in MCF7-K2 cells, which in turn inhibits 17b-E 2 -dependent MCF7-K2 cell proliferation.
DISCUSSION
Characterization of MCF7-K2 cells
There are several reports on the characteristics of MCF7 cells that show altered phenotypes in numerous laboratories. The main types of MCF7 cell are characterized by the expression of a functional ERa, but cellular response to exogenous estrogen (usually TAYLOR ET AL. 226 FIG. 7. 17b-E 2 but not 17a-E 2 enhances the inhibitory effect of antisense ERa ODN on ERa protein levels. Protein extracts (12 mg) from MCF7 cells transfected with scrambled ODN (A) or antisense ERa ODN (B) and treated with the indicated doses of 17b-E 2 (solid circles) or 17a-E 2 (open circles) for 24 hours were subjected to Western blot analysis as described in Materials and Methods. Data are the mean 6 SD of two experiments performed in triplicate (n 5 2) (p p , 0.05, p p p , 0.01, Student's paired t-test compared with untreated control).
17b-E 2 ) differs markedly. For example, MCF7-K1 and MCF7-K2 cells both contain functional ERa that bind 17b-E 2 . However, in MCF7-K1 cells, 17b-E 2 causes a number of effects, including ERa degradation through the proteosome pathway, activation of promoter ERE (estrogen responsive elements) by receptor transactivation, inhibition of ERa transcription and hence a reduction in the steady-state levels of ERa mRNA, and stimulation of 17b-E 2 -dependent proliferation. In contrast, MCF7-K2 cells only show some of these properties (Read et al., 1989) . To eliminate the confounding effects that 17b-E 2 administration might have on the potential mode of action of the antisense ODN used in this study, we used the MCF7-K2 cells. To ensure that the MCF7-K2 cells performed as described in the literature, we performed radioligand binding, proteosomal degradation, and growth analyses before subjecting the cells to transfection protocols. As predicted, the MCF7-K2 cells showed the expected features of this cell line's phenotype, including a proliferative response to 17b-E 2 .
Using the MCF7-K2 cells, we have demonstrated that three specific antisense ERa ODN directed against the human ERa gene specifically and efficiently inhibit ERa protein synthesis. Two of the oligos, oligo 1 and oligo 4, appear to work only in the presence of exogenous 17b-E 2 , whereas oligo 7 inhibited ERa protein levels in both the absence and presence of 17b-E 2 . More detailed studies with antisense oligo 7 show that both ERa protein and 3 H-E 2 binding were decreased by 50%-60%, suggesting that both methods measured the quantity of synthesized ERa. The values for K d and B max for 3 H-E 2 binding to MCF7-K2 cell extracts were similar to that reported by MacIndoe et al. (1982) but crucially different from those of others (Gyling and Leclercq, 1988; Otto, 1995) . This discrepancy is probably due to the subclone of MCF7 cells used in the present studies. Additionally, the relative molecular mass of immunoreactive MCF7 ERa protein was identical to that reported previously, with no additional isoforms or detectable proteolytic products (El Khissiin et al., 1997; Santagati et al., 1997) .
The other antisense molecules directed against the human ERa (oligos 1 and 4) did not show an effect on ERa protein levels or affect the ability of the protein to bind radioligand (data not shown) in the absence of 17b-E 2 but showed significant reductions in ERa levels when exposed to 17b-E 2 (Fig. 5) . These data do not correlate with the data obtained by others (Santagati et al., 1997) . In the studies of Santagati et al. (1997) MCF7 ERa protein levels increased in response to antisense ODN transfection with oligos 1 and 2, which are directed against the 59 region of the human ERa cDNA. In the present study, ERa levels remained constant in four of six cases and showed inhibitory effects on ERa protein levels, but only in the presence of exogenous 17b-E 2 . Oligos 1 and 4 showed no change in ERa levels in the absence of 17b-E 2 , but significant reductions in ERa protein levels were observed in the presence of 10 28 M 17b-E 2 (Fig. 5) . The reason for the discrepancy between these data is presumably due to the type of MCF7 cells used. The MCF7 cells used by Santagati et al. (1997) are probably different from the MCF7-K2 cells used in our studies, as several clones of the MCF7 cell line exist (Read et al., 1989) . These data suggest that the use of antisense ODN directed against endometrial ERa would perhaps require individual testing on a patient biopsy before any clinical trial.
Both the MCF7-K1 and MCF7-K2 cell clones contain high levels of ERa, but only the MCF7-K1 cells exhibit autologous downregulation of the ERa in response to 17b-E 2 (Santagati et al., 1997) . Although MCF7-K2 cells contain ligand-binding forms of the ER, 17b-E 2 does not affect ERa mRNA or protein levels (Read et al., 1989) . We were unable to demonstrate a decrease in ERa protein or mRNA levels in response to exogenous 17b-E 2 (Figs. 3 and 9 and Table 2 ), confirming that MCF7-K2 cells were used in the present study. However, using MCF7-K2 cells was important for this study because the autologous downregulating effect of exogenous 17b-E 2 on ERa expression that is seen in MCF7-K1 cells could have masked any modulation of ERa expression by the antisense ODN molecules. In other words, we can conclude that the inhibitory effect on the antisense ODN on ERa protein levels in the MCF7-K2 cells presented herein is due solely to the presence of the antisense ODN.
Although 17b-E 2 increases the degradation of ERa protein in MCF7-K1 cells in a dose-dependent and time-dependent manner TAYLOR ET AL. 228 FIG. 9. Antisense ERa oligo 7 has no effect on levels of ERa mRNA. (A) A representative ethidium bromide-stained agarose gel of RT-PCR products for ERa and b-actin. MCF7 cells transfected with scrambled or antisense ERa ODN were untreated (lanes 1, 6, 11) or treated with 10 29 M (lanes 2, 7, 12), 10 28 M (lanes 3, 8, 13), 10 27 M (lanes 4, 9, 14), or 10 26 M 17b-E 2 (lanes 5, 10, 15) for 24 hours. Extracted total RNA (1 mg) was subjected to RT-PCR with the primers shown in Table 1 and subjected to electrophoresis on 1.8% agarose gels impregnated with 0.5 mg/ml ethidium bromide. The image is representative of three separate experiments. (B) The densities of the bands shown in A were quantitated by video-assisted densitometry and corrected for the levels of b-actin. Data were normalized to nontransfected control cultures (the zero line) and are the mean 6 SD for three experiments in triplicate (n 5 3) (data were not significantly different, two-way ANOVA with Tukey's significance difference test). (Aronica and Katzenellenbogen, 1993; Ing and Ott, 1999) via the proteosome (Alarid et al., 1999; Nawaz et al., 1999) , this hormone also increases plasmid DNA transfer to MCF7 cells (Jain and Gerwitz, 1998) . This suggests that 17b-E 2 may have an effect on the MCF7 cell via the plasma membrane. Although a specific membrane ER has been reported recently (Nemere and Farach-Carson, 1998) , there is also evidence that 17b-E 2 interacts with the plasma membrane in a nonspecific manner (Dufy et al., 1979) and that other steroids directly interact with the plasma membrane (Zinder and Dar, 1999) . These data suggest that the addition of exogenous 17b-E 2 could enhance the effect of some antisense molecules through two or more mechanisms. First, 17b-E 2 could interact with a plasma membrane ER to activate the degradation of existing ER protein, or second, the hormone might interact with fundamental components of the plasma membrane to increase transfection efficiency or alter the physical characteristics of the lipofectamine-DNA complex to alter transfection efficiency. In our hands, 17b-E 2 had no effect on endogenous ERa protein expression and clearly is unable to induce ERa turnover via the proteosome pathway. Because ERa mRNA levels are not affected but protein levels decrease in the presence of antisense ERa ODN, we can conclude that antisense ERa ODN efficiently binds to the ERa mRNA, translation of nascent ERa protein is blocked, and endogenous ERa is cleared by a nonproteosomal pathway in MCF7-K2 cells.
The FITC-labeled ODN uptake experiment (Fig. 8) showed that 17b-E 2 enhanced ODN uptake and, therefore, transfection efficiency. Therefore, 17b-E 2 must alter the physical properties of the transfection process by interfering with either the liposome-DNA complex or the MCF7 cell plasma membrane to increase passage of DNA into the cell.
17b-E 2 enhanced FITC-labeled antisense ERa ODN (oligo 7) uptake and nuclear accumulation by MCF7-K2 cells. Theoretically, antisense ODN should be assimilated by cells through an episomal pathway and, therefore, should not appear in the nucleus (Cooper, 1996) . However, coating of DNA molecules with cationic liposomes, such as lipofectamine, may protect naked DNA and retarget the DNA through an alternative pathway to the MCF7-K2 nucleus, as is seen in keratinocytes (White et al., 2000) . This raises the possibility that first contact for the antisense ODN is heteronuclear RNA and not mature cytoplasmic RNA. This may explain why the levels of ERa mRNA showed an apparent, but not significant, decrease in the presence of antisense oligo 7 ERa ODN (Fig. 9B) . However, as ERa mRNA concentrations were not significantly different, an RNase H-dependent RNA degradation mechanism (Schlingensiepen and Schlingensiepen, 1997) involving the destruction of ERa mRNA is not implicated. The observed decrease in ERa protein levels with antisense oligo 7 is, therefore, presumably due to a steric blockade at the ERa translational start site.
The addition of exogenous 17b-E 2 , but not 17a-E 2 , to cultures augments both decreased ERa protein concentration and 3 H-E 2 binding to MCF7 extracts, suggesting that 17b-E 2 increases the transfection efficiency of the antisense ERa ODN. Additionally, 17b-E 2 does not override the antiproliferative effect of antisense oligo 7 but appears to enhance the antiproliferative effect. This is presumably due to increased transfection efficiency, leading to further reductions in ERa protein levels and, hence, ERa-dependent proliferation.
The ERa ODN described are not the first antisense molecule to be tested in our eventual goal, the uterine endometrium. An-
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FIG. 10. Antisense ERa oligo 7 inhibits 17b-E 2 -dependent proliferation of MCF7-K2 cells. MCF7-K2 cells (5000) plated in estrogen-deficient medium (1% charcoal-stripped serum) for 3 days were transfected with either scrambled oligo 7 (solid triangles) or antisense oligo 7 (open triangles) and treated with the indicated doses of 17a-E 2 (A) or 17b-E 2 (B) for a further 4 days. Medium was changed on alternate days. (C) MCF7-K2 cells (5000) were allowed to attach and grow for 24 hours. On day 0, cells were either not transfected (solid circles), transfected with scrambled oligo 7 (open circles), or transfected with antisense oligo 7 (open triangles) for 24 hours. On day 1, the medium on all cultures was changed for one containing 1% charcoal-stripped serum supplemented with 10 28 M 17b-E 2 . This medium was left in contact with the cells for the duration of the experiment. Growth was assessed using XTT formazan dye conversion at 490 nm. Data are the mean 6 SD of three experiments performed in quadruplicate (n 5 3) (p p , 0.05, p p p , 0.01, p p p p , 0.001, ANOVA with Tukey's significant differences test).
tisense ODN directed against Hox a10, Hox a11, calcitonin, and other target genes in laboratory animals have been described (Zhu et al., 1998; Bagot et al., 1999; Kunishige et al., 1999; Malayer et al., 1999) . This is to our knowledge, however, the first report of the use of antisense ODN against a human steroid receptor nuclear transcription factor. This is an important step forward because steroid receptors are implicated in numerous pathologic conditions, and the data presented may help in the elucidation of new gene targets. However, the diversity of steroid receptor-mediated effects suggests that significant systemic toxicity, a major concern in gene therapy (Cotter, 1997) , could occur with the use of antisense ERa oligo 7 in future human gene therapy clinical trials.
Although we envisage that antisense oligo 7 or similar molecules will be used solely as a topical application to the endometrial layer of the uterus and, thus, will have reduced toxic effects compared with a systemic application, there are two pieces of extra data that suggest any systemic toxic effect of a topically applied antisense ERa might be negligible. First, the application of bgalactosidase by transfection of the mouse uterus failed to elicit more than a few millimeters of penetration (Charnock-Jones et al., 1997) , and second, the female ERa knockout mouse does not exhibit gross systemic anatomic anomalies (Couse and Korach, 1999) . These data suggest that an antisense ODN would fail to penetrate further than a few millimetres into the human endometrium, and should it enter the vasculature, systemic organ damage would be limited. Additionally, unmodified oligonucleotides are rapidly destroyed in blood, suggesting that antisense ERa ODN, such as the ones described herein, would not cause significant toxicity (Agrawal et al., 1997) .
Accordingly, this paper has important implications for the control of diseases that involve transcriptional regulators, such as the steroid receptors, and especially diseases that are enhanced by 17b-E 2 through ERa. The data presented may lead to effective therapies for such diseases. The data presented also suggest that antisense ERa ODN have the potential to help unlock the mechanism of ERa synthesis and protein stability in target cells and help to dissect the relative roles of ERa and ERb in 17b-E 2 -dependent cells.
